New International Pharmaceutical Company Pro Bono Bio
Anglo/Russian Venture will have Important Humanitarian Objectives from Day 1
Pro Bono Bio™, a new international pharmaceutical company, is the result of a three year Anglo/Russian project, developed by Celtic Pharma Holdings in London. Pro Bono Bio has ambitious growth targets that will allow it to support a unique humanitarian mission. Pro Bono Bio combines global pharma expertise from the UK with international capital and matched funding from the Russian Corporation of Nanotechnologies (RUSNANO).
Pro Bono Bio is the first pharmaceutical company to have clear and specific humanitarian objectives from Day 1. Pro Bono Bio’s products will be priced in different geographic areas based on the region’s ability to pay. Importantly, Pro Bono Bio’s business model includes the provision of free drug donations to Africa based on the sales of its products at normal prices in the pharmaceutical markets of Western Europe. Pro Bono Bio’s shareholders are fully supportive of this unique approach.
John Mayo, CEO of Pro Bono Bio, said “Pro Bono Bio is an ambitious new international pharmaceutical company which expects to make a real difference to healthcare on a global scale. With an exciting pipeline of products and an innovative business model we intend to ensure that Pro Bono Bio can deliver attractive shareholder returns while at the same time making a growing contribution to healthcare budgets in areas such as The East African Community where resources are extremely limited.”
Other news from the department business & finance
